Masuo Yamaoka

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

Takahito Hara, Jun‐ichi Miyazaki, Hideo Araki et al. · PubMed · 2003 · 427 citations

Molecular Pharmacology, Androgen Receptor, Urology +12

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

Tomohiro Kaku, Takenori Hitaka, Akio Ojida et al. · Bioorganic & Medicinal Chemistry · 2011 · 126 citations · Full text

Medicinal Chemistry, Selective 17,20-Lyase Inhibitor, Potential Utility +9

Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys

Masuo Yamaoka, Takahito Hara, Takenori Hitaka et al. · The Journal of Steroid Biochemistry and Molecular Biology · 2012 · 116 citations

Steroid Synthesis, Medicinal Chemistry, Adrenal Gland +10

C17,20-lyase inhibitors. Part 2: Design, synthesis and structure–activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C17,20-lyase inhibitors

Nobuyuki Matsunaga, Tomohiro Kaku, Akio Ojida et al. · Bioorganic & Medicinal Chemistry · 2004 · 55 citations

Molecular Pharmacology, Medicinal Chemistry, C17,20-lyase Inhibitors +9

Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.

Takahito Hara, Kazuyo Nakamura, Hideo Araki et al. · PubMed · 2003 · 48 citations

Androgen-refractory Growth, Urology, Medicine +12